56436-24-9

Basic information

• Product Name: N-(2-methoxyethyl)-2-nitrobenzenamine
• Synonyms: N-(2-methoxyethyl)-2-nitrobenzenamine
• CAS NO: 56436-24-9
• Molecular Formula: C₉H₁₂N₂O₃
• Molecular Weight: 196.20318
• Mol File: 56436-24-9.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(2-methoxyethyl)-2-nitrobenzenamine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-methoxyethyl)-2-nitrobenzenamine(56436-24-9)
• EPA Substance Registry System: N-(2-methoxyethyl)-2-nitrobenzenamine(56436-24-9)

Safety Data

• Hazardous Substances Data: 56436-24-9(Hazardous Substances Data)

Upstream product

• 1493-27-2 ortho-nitrofluorobenzene 
• 109-85-3 2-methoxyethylamine 
• 7487-88-9 magnesium sulfate 
• 88-73-3 2-Chloronitrobenzene 

Downstream Products

• 56436-25-0 N¹-(2-methoxyethyl)benzene-1,2-diamine 
• 1338345-12-2 2-[2-(4-chlorophenyl)-1H-imidazol-4-yl]-1-[2-(methyloxy)ethyl]-1H-benzimidazole 
• 405211-51-0 1-(2-Methoxy-ethyl)-1H-benzoimidazol-2-ol 

Relevant articles and documents

Cell-Based Drug Discovery: Identification and Optimization of Small Molecules that Reduce c-MYC Protein Levels in Cells

Elevated expression of the c-MYC oncogene is one of the most common abnormalities in human cancers. Unfortunately, efforts to identify pharmacological inhibitors that directly target MYC have not yet yielded a drug-like molecule due to the lack of any known small molecule binding pocket in the protein, which could be exploited to disrupt MYC function. We have recently described a strategy to target MYC indirectly, where a screening effort designed to identify compounds that can rapidly decrease endogenous c-MYC protein levels in a MYC-amplified cell line led to the discovery of a compound series that phenocopies c-MYC knockdown by siRNA. Herein, we describe our medicinal chemistry program that led to the discovery of potent, orally bioavailable c-MYC-reducing compounds. The development of a minimum pharmacophore model based on empirical structure activity relationship as well as the property-based approach used to modulate pharmacokinetics properties will be highlighted.

Copper catalyzed aerobic oxidative cyclization and ketonization: One pot synthesis of benzoimidazo[1,2-: A] imidazolones

A highly efficient synthesis of benzoimidazo[1,2-a]imidazolone through a novel oxidative 5-exo-dig cyclization-ketonization cascade of 2-aminobenzimidazole, aldehyde and terminal alkyne has been explored under aerobic conditions. The reaction proceeds thr

IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS

Disclosed are compounds having the formula: wherein R1A, R1B, R2 and R3 are as defined herein, and methods of making and using the same.